Acland, G. M., et al. (2001). Gene therapy restores vision in a canine model of
childhood blindness. Nat. Genet. 28: 92 – 95.
Narfstrom, K., et al. (2003). Functional and structural recovery of the retina after
gene therapy in the RPE65 null mutation dog. Invest. Ophthalmol. Visual Sci. 44:
1663 – 1672.
Dejneka, N. S., et al. (2004). In utero gene therapy rescues vision in a murine model of
congenital blindness. Mol. Ther. 9: 182 – 188.
Lai, C. M., et al. (2004). Recombinant adeno-associated virus type 2-mediated gene
delivery into the Rpe65/ knockout mouse eye results in limited rescue. Genet.
Vaccines Ther. 2: 3.
Pang, J.J., et al. (2006). Gene therapy restores vision-dependent behavior as well as
retinal structure and function in a mouse model of RPE65 Leber congenital amaurosis.
Mol. Ther. 13: 565 – 572.
Acland, G. M., et al. (2005). Long-term restoration of rod and cone vision by single
dose rAAV-mediated gene transfer to the retina in a canine model of childhood
blindness. Mol. Ther. 12: 1072 – 1082.
Rolling, F. (2004). Recombinant AAV-mediated gene transfer to the retina: gene
therapy perspectives. Gene Ther. 11: S26 – S32.
Preising, M. N., and Heegard, S. (2004). Recent advances in early-onset severe retinal
degeneration: more than just basic research. Trends Mol. Med. 10: 51 – 54.
Jacobson, S. G., et al. (2005). Identifying photoreceptors in blind eyes caused by RPE65
mutations: prerequisite for human gene therapy success. Proc. Natl. Acad. Sci. USA 102:
6177 – 6182.
Provost, N., et al. (2005). Biodistribution of rAAV vectors following intraocular
administration: evidence for the presence and persistence of vector DNA in the optic
nerve and in the brain. Mol. Ther. 11: 275 – 283.
Le Meur, G., et al. (2005). Postsurgical assessment and long-term safety of recombinant
adeno-associated virus-mediated gene transfer into the retinas of dogs and primates.
Arch. Ophthalmol. 123: 500 – 506.
Gelatt, K. N., and MacKay, E. O. (1998). Distribution of intraocular pressure in dogs.
Vet. Ophthalmol. 1: 109 – 114.
Stephan, D. D., Vestre, W. A., Stiles, J., and Krohne, S. (2003). Changes in
intraocular pressure and pupil size following intramuscular administration of hydromorphone hydrochloride and acepromazine in clinically normal dogs. Vet. Ophthalmol. 6: 73 – 76.
Birch, D. G. (2004). Surrogate electroretinographic markers for assessing therapeutic
efficacy in the retina. Expert Rev. Mol. Diagn. 4: 693 – 703.
Serabian, M. A., and Pilaro, A. M. (1999). Safety assessment of biotechnology-derived
pharmaceuticals: ICH and beyond. Toxicol. Pathol. 27: 27 – 31.
Kimmelman, J. (2005). Recent developments in gene transfer: risk and ethics. BMJ 330:
79 – 82.
Shen, W. Y., et al. (2003). Practical considerations of recombinant adeno-associated
virus-mediated gene transfer for treatment of retinal degenerations. J. Gene Med. 5:
576 – 587.
Surace, E. M., and Auricchio, A. (2003). Adeno-associated viral vectors for retinal gene
transfer. Prog. Retinal Eye Res. 22: 705 – 719.
Fisher, S. K., Lewis, G. P., Linberg, K. A., and Verardo, M. R. (2005). Cellular remodeling
in mammalian retina: results from studies of experimental retinal detachment. Prog.
Retinal Eye Res. 24: 395 – 431.
Hennig, A. K., et al. (2004). AAV-mediated intravitreal gene therapy reduces lysosomal
storage in the retinal pigmented epithelium and improves retinal function in adult MPS
VII mice. Mol. Ther. 10: 106 – 116.
Faktorovich, E. G., Steinberg, R. H., Yasumura, D., Matthes, M. T., and LaVail, M. M.
(1992). Basic fibroblast growth factor and local injury protect photoreceptors from light
damage in the rat. J. Neurosci. 12: 3554 – 3567.
Dudus, L., et al. (1999). Persistent transgene product in retina, optic nerve and brain
after intraocular injection of rAAV. Vision Res. 39: 2545 – 2553.
Guy, J., Qi, X., Muzyczka, N., and Hauswirth, W. W. (1999). Reporter expression
persists 1 year after adeno-associated virus-mediated gene transfer to the optic nerve.
Arch. Ophthalmol. 117: 929 – 937.
Griffey, M., Macauley, S. L., Ogilvie, J. M., and Sands, M. S. (2005). AAV2mediated ocular gene therapy for infantile neuronal ceroid lipofuscinosis. Mol. Ther.
12: 413 – 421.
Hennig, A. K., et al. (2003). Intravitreal gene therapy reduces lysosomal storage in
specific areas of the CNS in mucopolysaccharidosis VII mice. J. Neurosci. 23: 3302 – 3307.
Bennett, J., et al. (1999). Stable transgene expression in rod photoreceptors after
recombinant adeno-associated virus-mediated gene transfer to monkey retina. Proc.
Natl. Acad. Sci. USA 96: 9920 – 9925.
Potter, M., Chesnut, K., Muzyczka, N., Flotte, T., and Zolotukhin, S. (2002).
Streamlined large-scale production of recombinant adeno-associated virus (rAAV)
vectors. Methods Enzymol. 346: 413 – 430.
Pearce-Kelling, S. E., et al. (2001). Calcium channel blocker D-cis-diltiazem does not
slow retinal degeneration in the PDE6B mutant rcd1 canine model of retinitis
pigmentosa. Mol. Vision 7: 42 – 47.
Kijas, J. W., et al. (2002). Naturally occurring rhodopsin mutation in the dog causes
retinal dysfunction and degeneration mimicking human dominant retinitis pigmentosa. Proc. Natl. Acad. Sci. USA 99: 6328 – 6333.
